More on GH
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $165.88 |
|
|||
| Open | $165.88 | ||||
| 52 Wk High | $5.84 | ||||
| 52 Wk Low | $5.49 | ||||
| Day High | $168.47 | ||||
| Day Low | $157.44 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,975,668 | ||||
- Form 144 Guardant Health, Inc. Filed by: Tariq Musa
- Form 4 Guardant Health, Inc. For: Oct 14 Filed by: Azar Alex M II
- PTAB again upholds TwinStrand patent challenged by Guardant Health
- TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent
- Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
- Form 144 Guardant Health, Inc. Filed by: Azar Alex M II
- Form 4 Guardant Health, Inc. For: Oct 12 Filed by: Azar Alex M II
- Guardant Health (GH) PT Raised to $200 at Morgan Stanley
- Guardant Health wins European approval for breast cancer companion diagnostic
- Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
Entities mentioned with GH
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
